A Phase 1, Single Centre, Three-part, Randomised, Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Single and Multiple Ascending Doses of Oral ONO-4053 and the Effects of Food on This Profile in Healthy Male and Female Subjects.
Phase of Trial: Phase I
Latest Information Update: 07 Jun 2012
At a glance
- Drugs ONO 4053 (Primary)
- Indications Allergic rhinitis
- Focus Adverse reactions
- 24 Jan 2012 Actual patients number (15) added as reported by ClinicalTrials.gov.
- 24 Jan 2012 Planned end date changed from 1 Dec 2011 to 1 Jul 2011 as reported by ClinicalTrials.gov.
- 24 Jan 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.